I agree mostly, however I don’t think this drug will get to market faster bing in a BP portfolio, if anything it will take much longer. The first thing a BP will do is study how this drug fits into their portfolio and the lifespan of other drugs. They will not cannabolize their own drug program. There are many times in the development of leronlimab that would have delayed or stopped if under a BP, Nader had nothing else to push but this one drug. Large corporations don’t move fast.